Scott Michael Palmer, MD

Professor of Medicine
Member in the Duke Clinical Research Institute
Vice-Chair for Research in the Department of Medicine
Professor in Immunology
Professor in Population Health Sciences
Core Faculty in Innovation & Entrepreneurship
Campus mail 2085 Msrb2 2 Genome Ct, Durham, NC 27710
Phone (919) 684-0245
Email address scott.palmer@duke.edu

Dr. Palmer leads a successful program of clinical, basic and translational research in transplantation and advanced lung diseases. He currently directs the pulmonary research program at the Duke Clinical Research Institute (DCRI) and serves as Vice Chair for Research in the Department of Medicine.

Dr. Palmer has over 150 peer reviewed publications, received numerous awards, including election into the American Society for Clinical Investigation (ASCI) in 2012, chaired many sessions at national and international meetings, serves regularly on NIH study sections, and is on the editorial board of many prominent journals. He is also Associate Director of the Clinical Research Training Program at Duke and has personally mentored over 40 pre-and post-doctoral trainees, many of whom are now engaged in their own successful research careers.

His scientific accomplishments include the first human studies to demonstrate the importance of innate immunity in transplant rejection and completion of a prospective multicenter study that improved CMV prevention after lung transplantation.

Current basic projects in the lab are studying the role of the matrix in the activation of innate immunity in pulmonary transplant rejection, and epithelial injury and repair in the development of toxin induced bronchiolitis obliterans. Translational and human projects are studying predictors of lung transplant survival in the UNOS database, immune monitoring to predict CMV infection and acute rejection after lung transplantation, and the use of novel inhaled antibiotics in lung transplantation. The lab is also using cutting edge whole exome genetic sequencing to identify genetic predictors of transplant rejection.

Dr. Palmer also leads trials coordinated through the DCRI that study the natural history and investigate new treatments for idiopathic pulmonary fibrosis (IPF), chronic lung transplant rejection, and posttransplant cytomegalovirus infection.

Education and Training

  • Fellow, Pulmonary Medicine, Medicine, Duke University, 1996 - 1999
  • Medical Resident, Medicine, Duke University, 1993 - 1996
  • M.H.S., Duke University, 2000
  • M.D., Duke University, 1993

Publications

Hadjiliadis, Denis, Thomas A. Sporn, John R. Perfect, Victor F. Tapson, R Duane Davis, and Scott M. Palmer. “Outcome of lung transplantation in patients with mycetomas..” Chest 121, no. 1 (January 2002): 128–34. https://doi.org/10.1378/chest.121.1.128.

PMID
11796441
Full Text

Reams, B Diane, and Scott M. Palmer. “Sublingual tacrolimus for immunosuppression in lung transplantation: a potentially important therapeutic option in cystic fibrosis..” Am J Respir Med 1, no. 2 (2002): 91–98.

PMID
14720063
Scholars@Duke

Hadjiliadis, D., V. F. Tapson, R. D. Davis, and S. M. Palmer. “Prognostic value of serum carcinoembryonic antigen levels in patients who undergo lung transplantation..” J Heart Lung Transplant 20, no. 12 (December 2001): 1305–9.

PMID
11744414
Scholars@Duke

Marom, E. M., Y. W. Choi, S. M. Palmer, D. M. DeLong, M. D. Stuart, and H. P. McAdams. “Reperfusion edema after lung transplantation: effect of daclizumab..” Radiology 221, no. 2 (November 2001): 508–14. https://doi.org/10.1148/radiol.2212010381.

PMID
11687697
Full Text

Palmer, S. M., R. H. Drew, J. D. Whitehouse, V. F. Tapson, R. D. Davis, R. R. McConnell, S. S. Kanj, and J. R. Perfect. “Safety of aerosolized amphotericin B lipid complex in lung transplant recipients..” Transplantation 72, no. 3 (August 15, 2001): 545–48. https://doi.org/10.1097/00007890-200108150-00036.

PMID
11502995
Full Text

Palmer, S. M., M. A. Baz, L. Sanders, A. P. Miralles, C. M. Lawrence, J. B. Rea, D. S. Zander, et al. “Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection..” Transplantation 71, no. 12 (June 27, 2001): 1772–76. https://doi.org/10.1097/00007890-200106270-00012.

PMID
11455257
Full Text

Garantziotis, S., D. N. Howell, H. P. McAdams, R. D. Davis, N. G. Henshaw, and S. M. Palmer. “Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome..” Chest 119, no. 4 (April 2001): 1277–80. https://doi.org/10.1378/chest.119.4.1277.

PMID
11296201
Full Text

Jackson, A., S. Palmer, R. D. Davis, A. Pappendick, E. Pearson, K. Savik, S. Ormaza, et al. “Cytokine genotypes in kidney, heart, and lung recipients: consequences for acute and chronic rejection..” Transplant Proc 33, no. 1–2 (February 2001): 489–90. https://doi.org/10.1016/s0041-1345(00)02106-0.

PMID
11266922
Full Text

Patel, V. S., R. H. Messier, S. M. Palmer, and R. D. Davis. “Coronary artery revascularization in eligible lung transplant recipients..” J Heart Lung Transplant 20, no. 2 (February 2001). https://doi.org/10.1016/s1053-2498(00)00490-3.

PMID
11250417
Full Text

Reinsmoen, N. L., S. M. Palmer, R. D. Davis, and F. E. Ward. “Presence of anti-HLA antibodies and correlation with development of BOS in lung recipients.” In Visuals of the Clinical Histocompatibility Workshop, edited by P. I. Terasaki, 31–32. ONE LAMBDA, INC, 2001.

Scholars@Duke

Pages